Oridonin Inhibits Metastasis of Human Ovarian Cancer Cells by Suppressing the MTOR Pathway

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2019 Jul 31

PMID 31360196

Citations 18

Authors

Ye Wang

Zhiling Zhu

Affiliations

Soon will be listed here.

Abstract

Introduction: Oridonin, which is isolated from the Chinese herb Rabdosia rubescens, has been reported to exhibit an anti-tumorous effect on different cancers. In this study, we investigated the molecular mechanism by which oridonin suppresses human ovarian cancer.

Material And Methods: The inhibition of oridonin on cell proliferation was assessed by CCK8 assay. Cell cycle and apoptosis were analyzed by flow cytometry, staining with propidium iodide (PI) or annexin-V/PI respectively. The metastasis rate was evaluated using a transwell migration assay. The expression of metastasis-associated genes and mTOR pathway related genes were detected by western blot.

Results: We demonstrated that oridonin suppressed the proliferation and blocked the cell cycle in G1/S phage and induced apoptosis in SKOV3 and A2780 cells ( < 0.01). We further found that the mTOR signaling pathway was suppressed by the treatment with oridonin, and the activation of the mTOR pathway attenuated the anti-tumorous effect of oridonin in human ovarian cancer cells, suggesting that the mTOR pathway was involved in the anti-tumorous process of oridonin. Additionally, the activation of the mTOR pathway by an exogenous activator reduced the expression level of FOXP3 ( < 0.01), thus providing evidence that FOXP3 is a factor that is necessary for the anti-tumorous effect of oridonin, and is negatively regulated by the mTOR pathway.

Conclusions: These results suggested that oridonin suppressed the mTOR signaling pathway, up-regulated the FOXP3 level, and inhibited metastasis of human ovarian cancer cells.

Citing Articles

The emerging role of glycolysis and immune evasion in ovarian cancer.

Jin B, Miao Z, Pan J, Zhang Z, Yang Y, Zhou Y Cancer Cell Int. 2025; 25(1):78.

PMID: 40045411 PMC: 11881340. DOI: 10.1186/s12935-025-03698-x.

Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin.

Su Y, Liu L, Lin C, Deng D, Li Y, Huang M Front Pharmacol. 2024; 15:1476739.

PMID: 39691396 PMC: 11649421. DOI: 10.3389/fphar.2024.1476739.

NLRP3 Negative Regulation Mechanisms in the Resting State and Its Implications for Therapeutic Development.

Kim Y, Lee S, Park Y Int J Mol Sci. 2024; 25(16).

PMID: 39201704 PMC: 11354250. DOI: 10.3390/ijms25169018.

Oridonin from : An emerging potential in cancer therapy - A comprehensive review.

Ali M, Khan N, Ali A, Akram H, Zafar N, Imran K Food Sci Nutr. 2024; 12(5):3046-3067.

PMID: 38726411 PMC: 11077219. DOI: 10.1002/fsn3.3986.

Oridonin inhibited epithelial-mesenchymal transition of laryngeal carcinoma by positively regulating LKB1/AMPK signaling.

Kou B, Shi Y, Zhou Z, Yun Y, Wu Q, Zhou J Int J Med Sci. 2024; 21(4):623-632.

PMID: 38464825 PMC: 10920846. DOI: 10.7150/ijms.92182.

References

Chambers A, Groom A, MacDonald I . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72. DOI: 10.1038/nrc865. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Hori S, Sakaguchi S . Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004; 6(8):745-51. DOI: 10.1016/j.micinf.2004.02.020. View

Ancuceanu R, Istudor V . Pharmacologically active natural compounds for lung cancer. Altern Med Rev. 2005; 9(4):402-19. View

Chen S, Gao J, Halicka H, Huang X, Traganos F, Darzynkiewicz Z . The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005; 26(3):579-88. View

Fontenot J, Rasmussen J, Williams L, Dooley J, Farr A, Rudensky A . Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005; 22(3):329-41. DOI: 10.1016/j.immuni.2005.01.016. View

Fontenot J, Rudensky A . A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005; 6(4):331-7. DOI: 10.1038/ni1179. View

Hsieh T, Wijeratne E, Liang J, Gunatilaka A, Wu J . Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 2005; 337(1):224-31. DOI: 10.1016/j.bbrc.2005.09.040. View

Zhang L, Zhao Y . The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol. 2007; 211(3):590-7. DOI: 10.1002/jcp.21001. View

10.

Zhou G, Chen S, Wang Z, Chen Z . Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res. 2007; 17(4):274-6. DOI: 10.1038/cr.2007.21. View

11.

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

12.

Chen G, Chen C, Wang L, Chang X, Zheng P, Liu Y . Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol. 2008; 180(8):5163-6. PMC: 2527697. DOI: 10.4049/jimmunol.180.8.5163. View

13.

Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T . Foxp3 expression in human cancer cells. J Transl Med. 2008; 6:19. PMC: 2386447. DOI: 10.1186/1479-5876-6-19. View

14.

Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M . T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A. 2008; 105(22):7797-802. PMC: 2409380. DOI: 10.1073/pnas.0800928105. View

15.

Pu C, Lan V, Lan C, Lang H . The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. Eur J Cancer Care (Engl). 2008; 17(4):340-9. DOI: 10.1111/j.1365-2354.2007.00865.x. View

16.

Huang J, Wu L, Tashiro S, Onodera S, Ikejima T . Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci. 2008; 107(4):370-9. DOI: 10.1254/jphs.08044fp. View

17.

Bast Jr R, Hennessy B, Mills G . The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9(6):415-28. PMC: 2814299. DOI: 10.1038/nrc2644. View

18.

Delgoffe G, Kole T, Zheng Y, Zarek P, Matthews K, Xiao B . The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009; 30(6):832-44. PMC: 2768135. DOI: 10.1016/j.immuni.2009.04.014. View

19.

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

20.

Yen Y, So S, Rose M, Saif M, Chu E, Liu S . Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009; 29(10):4083-92. View